Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Recurrent Ovarian Low Malignant Potential Tumors
Ovarian low malignant potential tumors may recur (come back) after they have been treated. The tumors may come back in the other ovary or in other parts of the body.
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - General Information About Ovarian Cancer
Ovarian cancer is a disease in which malignant (cancer) cells form in the ovaries.The ovaries are a pair of organs in the female reproductive system. They are in the pelvis, one on each side of the uterus (the hollow, pear-shaped organ where a fetus grows). Each ovary is about the size and shape of an almond. The ovaries make eggs and female hormones (chemicals that control the way certain cells or organs work in the body).Anatomy of the female reproductive system. The organs in the female reproductive system include the uterus, ovaries, fallopian tubes, cervix, and vagina. The uterus has a muscular outer layer called the myometrium and an inner lining called the endometrium. Ovarian cancer is the leading cause of death from cancer of the female reproductive system. Since 1992, the number of new cases of ovarian cancer has stayed about the same. The number of deaths from ovarian cancer has slightly decreased since 2002.It is hard to find ovarian cancer early. Early ovarian cancer may
Ovarian Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - General Information About Ovarian Germ Cell Tumors
Germ cell tumors of the ovary are uncommon,but aggressive,tumors,which are seen most often in young women or adolescent girls. These tumors are frequently unilateral and are generally curable if found and treated early. The use of combination chemotherapy after initial surgery has dramatically improved the prognosis for many women with these tumors.[ 1,2,3 ] Dysgerminomas One series ...
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Cellular Classification of Ovarian Epithelial Cancer
The following is a list of ovarian epithelial cancer histologic classifications. Serous cystomas: Serous benign cystadenomas.Serous cystadenomas with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low potential or borderline malignancy).Serous cystadenocarcinomas.Mucinous cystomas: Mucinous benign cystadenomas.Mucinous cystadenomas with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low potential or borderline malignancy).Mucinous cystadenocarcinomas.Endometrioid tumors (similar to adenocarcinomas in the endometrium): Endometrioid benign cysts.Endometrioid tumors with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low malignant potential or borderline malignancy).Endometrioid adenocarcinomas.Clear cell (mesonephroid) tumors: Benign clear cell tumors.Clear cell tumors with
Ovarian Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - About This PDQ Summary
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of ovarian germ cell tumors. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - General Information About Ovarian Low Malignant Potential Tumors
Tumors of low malignant potential (i.e., borderline tumors) account for 15% of all epithelial ovarian cancers. Nearly 75% of these tumors are stage I at the time of diagnosis. These tumors must be recognized because their prognosis and treatment is clearly different from the frankly malignant invasive carcinomas.A review of 22 series (953 patients) with a mean follow-up of 7 years revealed a survival rate of 92% for patients with advanced-stage tumors, if patients with so-called invasive implants were excluded. The cause of death was determined to be benign complications of disease (e.g., small bowel obstruction), complications of therapy, and only rarely (0.7%), malignant transformation. In one series, the 5-, 10-, 15-, and 20-year survival rates of patients with low malignant potential tumors (all stages), as demonstrated by clinical life table analysis, were 97%, 95%, 92%, and 89%, respectively. In this series, mortality was stage dependent: 0.7%, 4.2%, and 26.8% of patients
Ovarian Germ Cell Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information About Ovarian Epithelial Cancer
Related Summaries Note: Other PDQ summaries containing information related to ovarian epithelial cancer include the following: Genetics of Breast and Ovarian Cancer Ovarian Cancer Screening Ovarian Cancer Prevention Unusual Cancers of Childhood Statistics Note: Estimated new cases and deaths from ovarian cancer in the United States in 2010:[ 1 ] New cases: 21,880. Deaths: 13,850. Note: Some ...
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Questions or Comments About This Summary
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - nci_ncicdr0000062771-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Ovarian Cancer Prevention
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Stage Information for Ovarian Low Malignant Potential Tumors
Definitions: FIGOThe Féderation Internationale de Gynécologie et d'Obstétrique (FIGO) and the American Joint Committee on Cancer (AJCC) have designated staging to define ovarian low malignant potential tumors; the FIGO system is most commonly used.[1,2]Table 1. Carcinoma of the OvaryaStagea Adapted from FIGO Committee on Gynecologic Oncology.b In order to evaluate the impact on prognosis of the different criteria for allotting cases to stage Ic or IIc, it would be of value to know if rupture of the capsule was spontaneous, or caused by the surgeon; and if the source of malignant cells detected was peritoneal washings, or ascites.IGrowth limited to the ovaries.IaGrowth limited to one ovary; no ascites present containing malignant cells. No tumor on the external surface; capsule intact.IbGrowth limited to both ovaries; no ascites present containing malignant cells. No tumor on the external surfaces; capsules intact.IcbTumor either stage Ia or Ib, but with tumor on surface of one